Quick Answer
VACCINEX, INC. reported Research And Development Expense of $12.55 million for the year ending 2024.
- VACCINEX, INC. showed a decrease of -24.3% in Research And Development Expense from 2023 to 2024.
- This data is from VACCINEX, INC.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $3.39 million | Q3 2017: $4.29 million | Q1 2018: $4.45 million | Q2 2018: $5.51 million | Q3 2018: $5.31 million | Q1 2019: $7.41 million | Q2 2019: $7.30 million | Q3 2019: $6.54 million | Q1 2020: $5.41 million | Q2 2020: $4.56 million | Q3 2020: $7.33 million | Q1 2021: $5.51 million | Q2 2021: $4.06 million | Q3 2021: $3.63 million | Q1 2022: $2.97 million | Q2 2022: $3.84 million | Q3 2022: $3.43 million | Q1 2023: $3.81 million | Q2 2023: $5.05 million | Q3 2023: $4.36 million | Q1 2024: $3.38 million | Q2 2024: $3.86 million | Q3 2024: $3.17 million.
- Over the full 8 years of available data (2017 to 2024), VACCINEX, INC.'s Research And Development Expense has declined by 24.2%.
- Historical annual values: Fiscal year 2024: $12.55 million | Fiscal year 2023: $16.57 million | Fiscal year 2022: $13.98 million | Fiscal year 2021: $17.16 million | Fiscal year 2020: $21.55 million | Fiscal year 2019: $25.67 million | Fiscal year 2018: $22.35 million | Fiscal year 2017: $16.55 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: